Cannabix Technol Stock Price, News & Analysis

Cannabix Technologies (OTC: BLOZF) announces its participation in the upcoming National Drug and Alcohol Screening Association (NDASA) conference in Florida, where it will showcase its Marijuana Breath Test (MBT) alongside strategic partner Omega Laboratories.

The announcement follows Omega Laboratories' recent validation of the Cannabix MBT, which can simultaneously quantify Δ-9-THC, Δ-8-THC, CBD, and CBN in breath aerosols. The MBT system, comprising a Breath Collection Unit and Breath Cartridge, focuses on detecting recent marijuana use, unlike traditional urine, blood, and saliva tests that can detect THC for extended periods.

With cannabis now legal for medical use in 39 states and recreational use in 24 states, Cannabix is positioning itself at the forefront of breath-based drug detection. The company is currently conducting an operational review to scale up manufacturing, sales, marketing, and support capabilities in anticipation of growing demand.

Omega Laboratories has successfully completed method validation for a marijuana breath test using Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) Breath Collection Unit (BCU). The validated test method can simultaneously quantify THC, Δ-8-THC, CBD, and CBN in breath aerosols.

The Cannabix BCU features advanced capabilities including start-up air flow self-check, ambient air sample collection, split sample A/B configuration, and anti-cheating mechanisms. The system utilizes mass spectrometry for analysis, ensuring high forensic standards.

This breakthrough enables detection of recent marijuana use (within minutes to several hours), addressing limitations of traditional testing methods that detect usage over extended periods. Omega Laboratories is now incorporating breath testing into its service offerings, positioning the partnership as a leading solution for employers facing challenges with cannabis detection in various industries including law enforcement, workplace safety, and healthcare.

Cannabix Technologies (CSE: BLO) (OTC PINK: BLOZF) has signed a memorandum of understanding (MOU) with AlcoPro Inc. of Knoxville, TN, to collaborate on marketing the Cannabix Marijuana Breathalyzer (CMB) technology in the United States. As part of the initial agreement, AlcoPro will feature the CMB hardware in its 2025 product catalogue, which reaches over 70,000 businesses globally.

AlcoPro, established in 1982, is a leading distributor of drug and alcohol testing instruments. The MOU aims to establish preliminary marketing exposure for the CMB to AlcoPro's customers, assess market interest, and work towards a future distribution agreement. Cannabix has recently upgraded its Breath Collection Unit (BCU), a key hardware component used for portable detection of delta-9 THC in breath, and is advancing its validation work in the United States.

Cannabix Technologies (CSE: BLO, OTC: BLOZF) has announced significant updates to its Cannabix Marijuana Breathalyzer (CMB) technology. The company has enhanced its Breath Collection Unit (BCU) with new features including a smaller, lightweight design, removable rechargeable Li-ion battery, and modified sample collection cartridge capable of single or dual sample collection.

The improvements come amid growing concerns about marijuana-impaired driving in the United States, where cannabis is now legal in 39 states for medical use and 24 states for recreational use. According to a 2019 AAA Foundation survey, approximately 14.8 million U.S. drivers reported driving within one hour of using marijuana, with 70% believing they wouldn't get caught.

The technology focuses on 'recent use' detection of delta-9 THC, unlike traditional urine, blood, and saliva tests that can detect THC weeks after consumption. New features include ambient air collection capability, periodic quality assurance checks, and a streamlined user interface.

Cannabix Technologies has received positive certification from CEcert GmbH for its Breath Logix autonomous alcohol breathalyzer. The certification follows rigorous 6-month testing under Australian Standard AS 3547.1, including alcohol, drift, climatic, electromagnetic compatibility, and vibration testing. This certification enables marketing and sales in Australia and other jurisdictions. The device features patent-pending pre-calibrated cartridge technology, autonomous sobriety checking, identity confirmation, and real-time BAC reporting. The company is partnering with Breathalyser Sales & Service Pty for distribution in Australia, targeting employers, alcohol testing facilities, and various safety-critical industries including mining, oil and gas, industrial, trucking, and warehousing.

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) announced its participation in the upcoming Society of Forensic Toxicologists (SOFT) conference in October. Dr. Bruce Goldberger, Senior Advisor to Cannabix, will present the company's marijuana breathalyzer system at a workshop session titled 'Chasing Impairment – Advancement in Technologies or a Paradigm Shift? – You be the Judge!'

In collaboration with Omega Laboratories Inc., Cannabix has upgraded its Breath Collection Unit with new features to meet market and regulatory requirements. These include an 'on demand' quality assurance check, a startup self-check, and a new ambient air sample collection procedure. The sample collection cartridge has been modified to collect single or dual samples.

Omega scientists have successfully detected and quantified delta-9 THC in the low picogram range using Cannabix's technology. They have also developed a test method that detects, isolates, and quantifies delta-9 THC, delta-8 THC, CBN, and CBD from breath samples. The partnership aims to advance the development and commercialization of Cannabix's marijuana breathalyzer technology.

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) has initiated advanced discussions with Smartox of Irving, Texas for potential sales distribution of its Breath Logix Alcohol screening device. The company has shipped the device for evaluation, preliminary marketing, and business development purposes. Cannabix is rapidly advancing its Breath Logix alcohol screening devices with certification, manufacturing, regulatory, and distribution relationships.

The Breath Logix device offers a fast, accurate, and autonomous alcohol screening process for workplace testing. It features a unique pre-calibrated, replaceable alcohol sensor cartridge, eliminating costly calibrations. The device integrates with third-party access control and biometric systems, potentially expanding the reach of alcohol device distributors worldwide.

Cannabix Technologies and Omega Laboratories have reported positive early results from testing their marijuana breathalyzer technology. Omega has initiated pre-validation work to establish detection limits for delta-9 THC, the primary psychoactive component of cannabis. Omega scientists have successfully quantified delta-9 THC in low picogram ranges using Cannabix's Breath Collection Unit (BCU). The partnership aims to advance the development and commercialization of this technology, with Omega providing extensive expertise in forensic drug testing. The collaboration includes hardware refinement, marketing, and preparation for multiple validation studies.

Cannabix Technologies and Omega Laboratories have entered a strategic partnership to commercialize Cannabix's marijuana breathalyzer technology. The agreement, effective from May 15, 2024, involves research and development, validation, and commercialization phases. Omega will be the exclusive laboratory in North America for analyzing Cannabix's delta9 THC breathalyzer samples for five years. Omega will receive 1,000,000 common shares and up to 11,000,000 special warrants of Cannabix upon achieving specific milestones. The partnership aims to enhance drug detection technology and expand its market reach in North America.